loading page

Interferon-beta changes the expression of IL10, IL23A and FOXP3 on Multiple Sclerosis patients' T cells
  • +3
  • Hazal Gezmis,
  • Tansu Doran,
  • Saime Fusun Mayda Domac,
  • Deniz Yucel,
  • Rahsan Karaci,
  • Deniz Yat
Hazal Gezmis
Yeditepe University
Author Profile
Tansu Doran
Yeditepe University
Author Profile
Saime Fusun Mayda Domac
İstanbul Erenköy Ruh ve Sinir Hastalıkları Egitim ve Arastirma Hastanesi
Author Profile
Deniz Yucel
Acibadem Universitesi
Author Profile
Rahsan Karaci
İstanbul Erenköy Ruh ve Sinir Hastalıkları Egitim ve Arastirma Hastanesi
Author Profile
Deniz Yat
Yeditepe Universitesi
Author Profile

Abstract

Aim of the Study: Multiple sclerosis (MS) is an autoimmune disorder causing demyelination in axons. Available therapies target different molecules, but not all have therapeutic effects on disease progression, and this effect can only be seen after a long-time administration. Interferon beta (IFN-β), an MS therapy for many years, slows down the disease progression and reduces disease symptoms by targeting T cells. Yet, a considerable portion of the patient has experienced no therapeutic response to IFN-β. It is necessary to determine disease-specific biomarkers which allow early diagnosis or treatment of MS. Here, it was aimed to determine the effects of interleukin 10 (IL10) and 23 (IL23A) as well as forkhead box P3 (FOXP3) genes on MS after IFN-β therapy. Materials & Methods: Peripheral blood mononuclear cells (PBMCs) were extracted to isolate CD4+ and CD25+ T cells. Cytotoxicity assays were performed on each cell type for determining optimum drug concentration. Then, cells were cultured and determined drug concentration was administered to the cells to measure gene expressions with RT-PCR. Results: It was found that the cytotoxic effect of IFN-β was more efficient as the exposure time was expanded regardless of drug concentration. Moreover, CD25+ T lymphocytes were more resistant to IFN-β. IL23A was down-regulated, whereas FOXP3 was up-regulated at 48h in CD4+ T cells. For CD25+ T cells, the graded increase of FOXP3 was obtained while IL10 expression was gradually decreased throughout the drug intake, significantly. Conclusion: Although considerable change in expression was obtained, the long-term IFN-β effect on both genes and cells should be determined by follow-up at least a year. Keywords: MS, IFN-β, IL23A, FOXP3, IL10, T cells

Peer review status:ACCEPTED

11 Jan 2021Submitted to International Journal of Clinical Practice
13 Jan 2021Submission Checks Completed
13 Jan 2021Assigned to Editor
16 Jan 2021Reviewer(s) Assigned
30 Jan 2021Review(s) Completed, Editorial Evaluation Pending
26 Feb 20211st Revision Received
27 Feb 2021Submission Checks Completed
27 Feb 2021Assigned to Editor
28 Feb 2021Reviewer(s) Assigned
09 Apr 2021Review(s) Completed, Editorial Evaluation Pending
10 Apr 2021Editorial Decision: Accept